Overview
PreciseDx is an artificial intelligence company operating in the New York City healthcare sector [1]. Founded in 2020, the company focuses on oncology diagnostics [2]. PreciseDx leverages artificial intelligence for morphology-driven disease analysis, utilizing a proprietary technology called Morphology Feature Array (MFA) [2]. According to company information, the platform provides disease insights and actionable intelligence to support decision-making across the cancer care continuum [2]. The company operates in the medical and diagnostic laboratories industry [3] and employs 28 people [3].
Business address: 810 7th Ave, New York, New York, 10019. [6]
Growth & traction
Funding & milestones
1 events found for PreciseDx · 2026
SEC filing1 source$3.7M
Reported amount $3,699,998
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
In the news
Focus
- PreciseDx describes itself as "Innovating breast cancer diagnostic testing with PreciseBreast®. That's OncoIntelligence.".[5]
Something wrong or missing? Send an update. Fixed within 24 hours.